Literature DB >> 35935771

Neurological Manifestations of SARS-CoV-2 Infection: Protocol for a Sub-analysis of the COVID-19 Critical Care Consortium Observational Study.

Denise Battaglini1,2, Lavienraj Premraj3,4, Matthew Griffee5, Samuel Huth4,6, Jonathon Fanning4,6, Glenn Whitman7, Diego Bastos Porto8, Rakesh Arora9,10, Lucian Durham11, Eric Gnall12,13, Marcelo Amato14, Virginie Williams15, Alexandre Noel15, Sabrina Araujo De Franca15, Gordan Samoukovic16, Bambang Pujo17, David Kent18, Eva Marwali19, Abdulrahman Al-Fares20,21, Stephanie-Susanne Stecher22, Mauro Panigada23, Marco Giani24,25, Giuseppe Foti24,25, Paolo Pelosi1,26, Antonio Pesenti23,27, Nicole Marie White28, Gianluigi Li Bassi4,6,29, Jacky Suen4, John F Fraser4,30, Chiara Robba1,26, Sung-Min Cho7.   

Abstract

Introduction: Neurological manifestations and complications in coronavirus disease-2019 (COVID-19) patients are frequent. Prior studies suggested a possible association between neurological complications and fatal outcome, as well as the existence of potential modifiable risk factors associated to their occurrence. Therefore, more information is needed regarding the incidence and type of neurological complications, risk factors, and associated outcomes in COVID-19.
Methods: This is a pre-planned secondary analysis of the international multicenter observational study of the COVID-19 Critical Care Consortium (which collected data both retrospectively and prospectively from the beginning of COVID-19 pandemic) with the aim to describe neurological complications in critically ill COVID-19 patients and to assess the associated risk factors, and outcomes. Adult patients with confirmed COVID-19, admitted to Intensive Care Unit (ICU) will be considered for this analysis. Data collected in the COVID-19 Critical Care Consortium study includes patients' pre-admission characteristics, comorbidities, severity status, and type and severity of neurological complications. In-hospital mortality and neurological outcome were collected at discharge from ICU, and at 28-days. Ethics and Dissemination: The COVID-19 Critical Care Consortium main study and its amendments have been approved by the Regional Ethics Committee of participating sites. No further approval is required for this secondary analysis. Trial Registration Number: ACTRN12620000421932.
Copyright © 2022 Battaglini, Premraj, Griffee, Huth, Fanning, Whitman, Bastos Porto, Arora, Durham, Gnall, Amato, Williams, Noel, De Franca, Samoukovic, Pujo, Kent, Marwali, Al-Fares, Stecher, Panigada, Giani, Foti, Pelosi, Pesenti, White, Li Bassi, Suen, Fraser, Robba, Cho and the COVID-19 Critical Care Consortium.

Entities:  

Keywords:  COVID-19; disability; neurological complications; neurological outcome; stroke

Year:  2022        PMID: 35935771      PMCID: PMC9355612          DOI: 10.3389/fmed.2022.930217

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


Introduction

Coronavirus disease 2019 (COVID-19) presents with a wide spectrum of symptoms, from mild to severe, up to sequential organ failure and multiple-organ dysfunction (1). Reports of neurological manifestations associated with COVID-19 are increasing in the literature (2, 3). COVID-19 neurological signs can involve either the central nervous system (CNS), peripheral nervous system (PNS), or musculoskeletal system. Fatigue, myalgia, impaired sense of smell and taste, and headache are common neurological manifestations of COVID-19 (4, 5), whereas dizziness, confusion, delirium, agitation, stroke, hypoxic ischemic injury, seizures, encephalitis and coma among others have been reported neurological complications of hospitalized patients (4, 5). In some cases, neurological manifestations have been reported even without a primary respiratory involvement (4, 5). Several explanations have been proposed for the cause of neurological symptoms of COVID-19, but the underlying pathophysiology is not well defined. Putative mechanisms include viral neurotropism, a hyperinflammatory and hypercoagulable state, or pathological brain–lung crosstalk (6). Endothelial dysregulation (7–9) and pro-thrombotic state (10–12) have been widely suspected to be the possible main contributors of the increased risk of neurologic events. Indeed, COVID-19 patients are at high risk of hypoxia, hypotension, and microvascular abnormalities (13–15) which can promote neuroinflammation and excitotoxicity and increased permeability of the blood brain barrier (16). The risk is even more increased by the use of extracorporeal membrane oxygenation (ECMO) support that is a salvage option in COVID-19 critically ill patients with refractory hypoxemia (17). Prior studies suggested a possible association between neurological complications and mortality (18), but more information is required to delineate this association with respect to regional variation, as well as the risk factors associated to the occurrence of neurological complications (19). The aim of this study is to estimate the incidence of neurological complications in critically ill COVID-19 patients. Associations between neurological complications, patient-level variables and outcomes will also be assessed.

Methods and Analysis

Study Design

This is a pre-planned sub-analysis of a large international multicenter observational study of patients in participating intensive care units (ICUs) with COVID-19 of the COVID-19 Critical Care Consortium incorporating the ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (ECMOCARD). The collaborative consists of investigators from the Asia-Pacific extracorporeal life support organization (APELSO) in collaboration with centers within the SPRINT-SARI and International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Network. In Australia, this study is also supported by collaboration with the “National registry on the treatment and outcomes of patients requiring ECMO” (EXCEL Registry). A panel of 13 experts in neurocritical care was created in 2020 together with the main protocol of the COVID-19 Critical Care Consortium by the Steering committee of the consortium. The panel planned this subanalysis and the electronic case report form (eCRF) in February 2020 and followed it up through monthly meeting. The study will be conducted in compliance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) (20) (Supplementary Item 1). Trial registration number: ACTRN12620000421932.

Objectives

The primary objective is to identify and describe the type and incidence of neurological complications in COVID-19 patients before and after admission to ICU, for all ICU patients selected patient subgroups (sex, age, country, treatment, COVID-19 wave). Secondary objectives include: To evaluate the effect of neurological complications on outcomes after COVID-19, i.e., mortality, duration of ICU and hospital stay, neurological outcome (modified Rankin scale, mRS) at discharge, incidence of delirium and cognitive outcome at discharge. To identify factors related to the occurrence of neurological complications (including neurological injury due to the antiviral therapy).

Specific Sub-analysis

Secondary sub-analyses will also include the investigation of (1) magnetic resonance images (MRI) or computed tomography (CT) features; (2) serum biomarkers [neuronal injury markers (S100B, neuron specific enolase, NSE), endothelial dysfunction markers, inflammatory markers].

Inclusion and Exclusion Criteria

The COVID-19 Critical Care Consortium included all COVID-19 patients (≥18 years) admitted to ICU for receiving critical care with confirmed or suspected COVID-19 respiratory disease. For this specific sub-analysis, further inclusion criteria will be available data on neurological complications/manifestations. Patients treated with mechanical ventilation or ECMO for other causes than COVID-19 will be excluded.

Study Procedures and Setting

The protocol of the main study has been previously published (21). Participants in the COVID-19 Critical Care Consortium Observational Study are recruited at multiple sites in over 52 countries from 1st January 2020 onwards.

Data Collection

Data collection started from the commencement of COVID-19 pandemic and is planned to continue until completion of COVID-19 pandemic, as judged by the World Health Organization. According to the COVID-19 Critical Care Consortium Observational Study protocol (21) and neurological sub-study protocol, the following data will be collected: general patient characteristics, age, gender, body mass index (BMI), country, previous chronic comorbidities, scores of severity; premorbid scores [modified Rankin scale (0–6 points), Figure 1; new neurological complications, laboratory findings, imaging, and management of neurological complications (Supplementary Item 2); patient outcome (mortality at discharge, at 28-days, withdrawal of life-saving therapy and reason; mRS at ICU discharge, mRS at 28 days after discharge). Main eCRF of the COVID-19 critical care consortium study and neuro sub-study are provided in the Supplementary Items 3, 4.
Figure 1

Modified Rankin Scale (mRS). The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6 (from 0 = no symptoms to 6 = dead). A score of 0–3 indicate mild to moderate disability and a score of 4–5 indicate severe disability. From Wade (22).

Modified Rankin Scale (mRS). The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6 (from 0 = no symptoms to 6 = dead). A score of 0–3 indicate mild to moderate disability and a score of 4–5 indicate severe disability. From Wade (22).

Data Management

Data are stored in the central online eCRF database managed by the Oxford University in anonymized form, in order to preserve confidentiality of information in medical records. The Username and password will be assigned by the Oxford University during the registration process for individual Research Coordinators or Site Investigators. All electronic data transfer between study site and database will be username and password protected. The Participant List of the Neurology sub-study is maintained locally and is not to be transferred to any other location. confidentiality of the participant will be maintained unless disclosure is required by law. Data entry and management will be coordinated by ISARIC and ECMOCARD steering committee, including programming and data management support. ANZIC-RC and ISARIC will act as custodian of the data. The University of Queensland (Australia) will receive data from the data custodians via data sharing agreements. The management committee of the trial will take responsibility for the content and integrity of any data.

Definition of Neurological Complications

Definition of neurological complications (23–32) is listed in Table 1.
Table 1

Definition of neurological complications/manifestations.

Neurological complication Definition
Central nervous system
Ischemic stroke (23)Neurological deficit due to an acute focal injury in the central nervous system caused by vascular involvement such as occlusion and cerebral infarction.
Intracranial hemorrhage (23, 24)Bleeding that occurs inside the skull. Hemorrhagic stroke: neurological deficit due to an acute focal injury in the central nervous system caused by vascular involvement with intracerebral or subarachnoid hemorrhage. Subdural hematoma: collection of blood under the dura mater.
Encephalitis/meningitis (25)Severe inflammatory disorder of the brain or meninges or parenchyma.
Transverse myelitis and other spinal cord pathologies (26)Inflammatory disorder with acute or subacute motor-sensory and autonomic spinal cord dysfunction.
Epilepsy, seizures, and generalized convulsive status epilepticus (27, 28)Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, and by neurobiological, cognitive, psychological, and social consequences. Seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Generalized convulsive status epilepticus is defined in adults and children older than 5 years as ≥5 min of (1) continuous seizure or (2) two or more discrete seizures between which there is incomplete recovery of consciousness.
Delirium (29)Acute change in consciousness and attention caused by an organic condition.
Peripheral nervous system
Guillain-Barré Syndrome (30)Inflammatory immune-mediated polyradiculoneuropathy with acute onset that manifests with tingling, progressive weakness, autonomic disfunction and pain.
Critical illness myopathy/neuropathy (31)Neuromuscular weakness in the intensive care setting.
Hypogeusia/hyposmia (32)Quantitative disorders characterized by reduction of taste or smell.
Others
Hypoxic-ischemic brain injury (33)Reduction in blood supply, oxygen supply or utilization that determines a decreased oxygen delivery to the brain and post cardiac arrest hypoxic ischemic brain injury (reduction in blood supply, oxygen supply or utilization that determines a decreased oxygen delivery to the brain due to cardiac arrest).
Definition of neurological complications/manifestations.

Statistical Analysis Plan

Planned analyses will comprise of descriptive summaries and regression-based methods for estimating associations between patient-level variables, neurological complications, and outcomes. Descriptive statistics for summarizing the study cohort will be presented as medians with interquartile ranges and frequencies with percentages for continuous and categorical variables, respectively. As an observational study, missing data are expected; a data completeness summary will accompany descriptive summaries for all variables considered. The incidence of neurological complications will be calculated as the number of events per 1,000 ICU days and as the number of events divided by the total number of ICU admissions. Incidence will be estimated per complication using logistic and Poisson regression; Poisson models will include patient days as an offset to account for varying ICU exposure. Baseline models will be adjusted for patient-level variables (e.g., sex, age, country) and calendar time to account for the timing of different COVID-19 waves. Additional covariates will be informed by univariate analysis and penalized regression techniques to address the secondary objective related to incidence. Analysis of associations between neurological complications and clinical outcomes will be examined using generalized linear mixed models for binary outcomes and parametric survival models for time-to-event outcomes. Evidence of potential associations, including patient demographics and clinical signs assessed during ICU admission, will initially be assessed using univariate analysis. Results of univariate analysis will be used to inform variable selection for multivariable analysis. Multivariable models for all study objectives will be adjusted for known confounders as fixed or random effects, including study center, country, and calendar time. Model results will be presented as odds ratios (binary outcomes), relative risks (count outcomes) or hazard ratios (time-to-event outcomes) with 95% confidence intervals and p-values from hypothesis tests as appropriate.

Study Status

The protocol version is 1.2.8 of the COVID-19 Critical Care Consortium Observational Study available at https://www.elso.org/COVID19/ECMOCARD.aspx. Data collection started from the commencement of COVID-19 pandemic and is planned to continue until completion of COVID-19 pandemic, as judged by the World Health Organization, as reported in the protocol.

Discussion

This neurological sub-analysis of the COVID-19 Critical Care Consortium Observational Study is designed with the aim to obtain a detailed overview on neurological complications in a large international multicenter cohort of critically ill COVID-19 patients admitted to ICU, to determine incidence and risk factors of neurological complications, and the association of neurological complications with outcome. This study will provide real-time global data without geographic restrictions. In the latest 2 years, knowledge has increased regarding extra-pulmonary complications of COVID-19 and their effect on outcome. Severe COVID-19 disease potentially involves multiple organs, including pulmonary, coagulation, cardiac, neurological, renal, hepatic, and gastrointestinal manifestations (34). Many neurological manifestations have been described recently in small observational studies, but additional evidence is needed from large multicentric cohorts. For this reason, in the present study we aim to depict the incidence, risk factors, and impact on outcome of neurological complications in critically ill COVID-19 patients from a large observational multicentric cohort. Data regarding pre-admission neurological manifestations, in-hospital neurological complications as well as ICU-and-hospital length of stay, neurological outcome (mRS), and mortality are available in the eCRF. This sub-analysis of the COVID-19 Critical Care Consortium Observational Study was pre-planned during the first/second wave of the pandemic (late 2020), thus increasing the data quality and minimizing the chance of spurious results and limiting the potential of exploratory learning. The number of patients included in the main study is continuously growing since the beginning of pandemic, allowing to obtain a large sample size, which can provide important information on the current incidence and characteristics of neurological manifestations in COVID-19 patients, evaluating potential associations between predictors and development of neurological complications, and assessing outcomes at discharge from ICU and from hospital and 28-days patients' outcomes. The included patients will be from different countries and centers, including low incoming countries. The patients will be also included during different waves and years of the pandemic, before and after the advent of vaccination campaigns, and with different variants of COVID-19 (i.e., omicron, delta, etc.). This will provide interesting insights on the differences in epidemiology, management strategies, geographical, and economical characteristics of COVID-19 adult patients who manifest neurological complications admitted to ICU. This global research context will provide the lens through which the study as well as its methodological approaches, findings, conclusions, and recommendations can be viewed.

Incidence and Types of Neurological Manifestations and Complications of COVID-19

The importance of investigating neurological manifestations in COVID-19, assessing their risk factors, and association with outcome is justified by the increasing identification in the available literature of many studies which reported high morbidity and mortality and poor neurological outcome in COVID-19 patients who manifest neurological complications, with the need for identifying and investigating such alterations in a bigger cohort of COVID-19 critically ill patients. Indeed, regarding each of the identified neurological manifestations of COVID-19, the data are fragmentary and come from different small cohorts. Myalgia, dysgeusia, and taste dysfunction were frequently reported (33% of cases), altered mental status in 32%, headache 29%, encephalopathy 26%, alteration of consciousness 13%, stroke 12%, dizziness 10%, vision impairment 6%, intracerebral hemorrhage, 5%, seizure 4%, encephalitis 2%, and GBS 1% (35). Intracranial hemorrhage was identified in 477 patients with a prevalence of 0.85% and a mortality of 52% suggesting a very poor prognosis despite rare incidence (36). The prevalence of intracranial hemorrhage, ischemic stroke, and hypoxic ischemic brain injury was higher in patients with COVID-19 who underwent ECMO support (5.9%) with a mortality of 92% (17). Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis have been reported in 46 patients with COVID-19 only, of whom 32% died (37).

Risk Factors for Neurological Manifestations and Complications of COVID-19

Regarding risk factors and association of neurological manifestations with outcome, a systematic review revealed that patients who suffer from a severe COVID-19 have more CNS involvement, neurological symptoms, and association with stroke. More severe patients had higher D-dimer and C-reactive protein levels than non-severe patients and presented multiple organ involvement (38). Myalgia, acute cerebrovascular disease, elevated creatin kinase, and lactate dehydrogenase were associated with more severe disease (3), while delirium on admission is a good predictor of mortality outcome in COVID-19 (39). In a cohort of 1,072 patients, age, headache at presentation, preexisting neurologic disease, invasive mechanical ventilation, and neutrophil/lymphocyte ratio ≥ 9 were independent predictors of new neurologic complications (40). In another study, the CT lung disease severity score was predictive of acute abnormalities on neuroimaging in patients with COVID-19 with neurologic manifestations (41). In a retrospective analysis, previous neurological history did not impact mortality, whereas new neurological manifestations were predictors of death (42). In a large cohort of 3,055 COVID-19 patients, preexisting neurological disorders were associated with higher risk of developing new neurological manifestations (2).

Outcome of COVID-19 Patients With Neurological Manifestations and Complications

Patients affected by COVID-19 with neurological manifestations were noted to have an impaired quality of life in 49% of cases, with a residual disability at 6-months in 52%, impaired cognition in 69%, and persistence of anxiety and depression in 32% (43). Neurological outcome in 135 patients with COVID-19 at 3-months follow-up was impaired (44), and a significant patient number still suffer from neurological sequelae 1 year after SARS-CoV-2 infection (45). A large multicentric study investigating delirium in 4,530 COVID-19 patients revealed that acute brain dysfunction was highly prevalent and prolonged in critically ill patients with COVID-19, with benzodiazepines and lack of family visitation identified to be risk factors for its development (46). After 6 months, in a cohort of 236,379 patients with COVID-19, neurological and psychiatric manifestations had an estimated incidence of 33.62 and 12.84%, respectively (47). Clinical outcome was evaluated in a cohort of 267 patients, concluding that patients with cerebrovascular disease had the worst prognosis (48).

Potential Pitfalls and Unintended Effects of This Study

Taken together, a large number of case reports and case series, despite coming mainly from small cohorts and local studies raise interest around the need for clarification about type and incidence of COVID-19 neurological manifestations, risk factors, and association with outcome on large scale, thus encouraging to better plan for possible management and therapeutics for neurological complications in critically ill COVID-19 patients. A limitation of current available data in the literature is that most of the data come from small cohorts, that could be addressed by using the larger COVID-19 Critical Care Consortium. Our study is unique in a way that we can address both limitations by studying the questions with international cohort with granular neurological variables. According to the design of our study, no unintended effects are expected. However, some limitations should be addressed. Being an observational study, it can be exposed to bias and confounding. Additionally, it cannot be used to demonstrate causality.

Conclusions

In conclusion the present study will provide new information on a global scale regarding the incidence and type of neurological complications, risk factors, and associated outcomes in COVID-19 with clinical applications.

Ethics Statement

The study will be conducted in compliance with the current version of the COVID-19 Critical Care Consortium and Neurologic sub-study protocol. Protocol version and subsequent amendment will be submitted and approved by the Local Ethics Committee in compliance to national standards. Sites wishing to participate will be required to provide the COVID-19 Critical Care Consortium Research Coordinator with an Institutional Review Board (IRB) approval certificate. The regulations of the COVID-19 Critical Care Consortium state that this study will not require individual patient consent as an observational study. Data of this study is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. However, for any location that deems individual consent necessary, informed consent will be managed in accordance with the local regulations of each involved IRB. In particular, in patients who meet the inclusion/exclusion criteria, informed consent will be obtained directly from the patient, either before the study or retrospectively in case the patient is unconscious at the time of enrolment. If the patient is unable to provide a consent form upon admission, informed consent will be obtained by his/her next of kin.

Author Contributions

DB drafted the manuscript and planned the methodology and the outcomes. S-MC and CR revised the manuscript and supervised the methodology and outcomes. DB, LP, MGr, SH, JF, GW, DBP, RA, LD, EG, MA, VW, AN, SD, GS, BP, DK, EM, AA-F, S-SS, MP, MGi, GF, PP, AP, NW, GL, JS, CR, and S-MC helped in the revision and methodology and approved the final version. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Bill & Melinda Gates Foundation, Grant number INV-034765; The University of Queensland; The Wesley Medical Research; The Prince Charles Hospital Foundation; The Health Research Board of Ireland. GL was a recipient of the BITRECS fellowship; the BITRECS project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 754550 and from the La Caixa Foundation (ID 100010434), under the agreement LCF/PR/GN18/50310006. JS was funded by the Advance Queensland fellowship program.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Prefix/First Name/Last Name Site Name
Eugeni Roure Marta RoureThe University of Queensland, Australia
Fatima NasrallahThe Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia
Katie McMahonSchool of Clinical Sciences and Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland, Australia
Judith BellapartRoyal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Fabio Silvio TacconeErasmus Hospital, Free University of Brussels, Evere, Belgium
Tala Al-Dabbous Huda Alfoudri Mohammed ShamsahAl Adan Hospital
Subbarao Elapavaluru Ashley Berg Christina HornAllegheny General Hospital
Yunis MayasiAvera McKennan Hospital & University Health Centre
Stephan SchrollBarmherzige Bruder Regansburg
Dan Meyer Jorge Velazco Ludmyla Ploskanych Wanda Fikes Rohini Bagewadi Marvin Dao Haley White Alondra Berrios Laviena Ashley Ehlers Maysoon Shalabi-McGuire Trent WittBaylor Scott & White Health
Lorenzo Grazioli Luca LoriniBergamo Hospital
E. Wilson Grandin Jose Nunez Tiago ReyesBeth Israel Deaconess Medical Centre
Diarmuid O'Briain Stephanie HunterBox Hill Hospital
Mahesh Ramanan Julia AffleckCaboolture Hospital
Hemanth Hurkadli Veerendra Sumeet Rai Josie Russell-Brown Mary NourseCanberra Hospital
Mark Joseph Brook Mitchell Martha TenzerCarilion Clinic
Ryuzo AbeChiba University Graduate School of Medicine
Hwa Jin Cho In Seok JeongChonnam National University Hospital
Nadeem Rahman Vivek KakarCleveland Clinic- Abu Dhabi
Nicolas BrozziCleveland Clinic - Florida
Omar Mehkri Sudhir Krishnan Abhijit Duggal Stuart HoulthamCleveland Clinic - Ohio
Jerónimo GrafClinica Alemana De Santiago
Roderigo Diaz Roderigo Orrego Camila Delgado Joyce González Maria Soledad Sanchez Michael Piagnerelli Josefa Valenzuela SarrazinClinica Las Condez
A/Prof. Gustavo Zabert Lucio Espinosa Paulo Delgado Victoria DelgadoClinica Pasteur National- University of Comahue
Diego Fernando Bautista Rincón Angela Maria Marulanda Yanten Melissa Bustamante DuqueClinica Valle de Lilli
Daniel BrodieMedical ICU, Columbia College of Physicians and Surgeons, New-York-Presbyterian Hospital, NY, NY, USA
Alyaa Elhazmi Abdullah Al-HudaibDr Sulaiman Alhabib Medical Group – Research Center, Riyadh, Saudi Arabia
Maria CallahanEmory University Healthcare System
M. Azhari Taufik Elizabeth Yasmin Wardoyo Margaretha Gunawan Nurindah S Trisnaningrum Vera Irawany Muhammad RayhanFatmawati Hospital
Mauro Panigada Antonio Pesenti Alberto Zanella Giacomo Grasselli Sebastiano Colombo Chiara Martinet Gaetano FlorioFondazione IRCCS Policlinico of Milan (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Massimo Antonelli Simone Carelli Domenico L. GriecoFondazione Policlinico Universitario Agostino Gemelli IRCCS
Motohiro AsakiFujieda Municipal General Hospital
Kota HoshinoFukuoka University
Leonardo Salazar Mary Alejandra Mendoza MonsalveFundación Cardiovascular de Colombia
John Laffey Bairbre McNicholas David CosgraveGalway University Hospitals
Joseph McCaffrey Allison BoneGeelong Hospital
Yusuff HakeemGlenfield Hospital
James Winearls Mandy TallottGold Coast University Hospital
David Thomson Christel Arnold-Day Jerome Cupido Zainap Fanie Malcom Miller Lisa Seymore Dawid van StraatenGroote Schuur Hospital
Ali Ait Hssain Jeffrey Aliudin Al-Reem Alqahtani Khoulod Mohamed Ahmed Mohamed Darwin Tan Joy Villanueva Ahmed ZaqoutHamad General Hospital - Weill Cornell Medical College in Qatar
Ethan Kurtzman Arben Ademi
Ana Dobrita Khadija El Aoudi Juliet SeguraHartford HealthCare
Gezy GiwangkancanaHasan Sadikin Hospital (Adult)
Shinichiro OhshimoHiroshima University
Javier OsatnikHospital Alemán
Anne JoostenHospital Civil Marie Curie
Antoni Torres Minlan Yang Ana MotosHospital Clinic, Barcelona
Carlos LunaHospital de Clínicas
Francisco ArancibiaHospital del Tórax
Virginie Williams Alexandre NoelHospital du Sacre Coeur (Universite de Montreal)
Nestor LuqueHospital Emergencia Ate Vitarte
Marina FantiniHospital Mater Dei
Ruth Noemi Jorge García Enrique Chicote AlvarezHospital Nuestra Señora de Gracia
Anna GretiHospital Puerta de Hierro
Adrian CeccatoHospital Universitari Sagrat Cor
Angel SanchezHospital Universitario Sant Joan d'Alacant
Ana Loza VazquezHospital Universitario Virgen de Valme
Ferran Roche-Campo Diego Franch-LlasatHospital Verge de la Cinta de Tortosa
Divina TuazonHouston Methodist Hospital
Marcelo Amato Luciana Cassimiro Flavio Pola Francis Ribeiro Guilherme FonsecaINCOR (Universidade de São Paulo)
Heidi Dalton Mehul Desai Erik Osborn Hala DeebINOVA Fairfax Hospital
Antonio Arcadipane Gennaro Martucci Giovanna Panarello Chiara Vitiello Claudia Bianco Giovanna Occhipinti Matteo Rossetti Raffaele CuffaroISMETT
Sung-Min Cho Glenn WhitmanJohns Hopkins
Hiroaki Shimizu Naoki MoriyamaKakogawa Acute Care Medical Center
Jae-Burm KimKeimyung University Dong San Hospital
Nobuya KitamuraKimitsu Chuo Hospital
Johannes GebauerKlinikum Passau
Toshiki YokoyamaKouritu Tousei Hospital
Abdulrahman Al-Fares Sarah Buabbas Esam Alamad Fatma Alawadhi
Kalthoum AlawadiAl-Amiri and Jaber Al-Ahmed Hospitals, Kuwait Extracorporeal Life Support Program
Hiro TanakaKyoto Medical Centre
Satoru Hashimoto Masaki YamazakiKyoto Prefectural University of Medicine
Tak-Hyuck OhKyung Pook National University Chilgok Hospital
Mark Epler Cathleen Forney
Louise KruseJared Feister Joelle Williamson Katherine GrobengieserLancaster General Health
Eric Gnall Sasha Golden Mara Caroline Timothy Shapiro Colleen Karaj Lisa Thome Lynn Sher Mark Vanderland Mary Welch Sherry McDermottLankenau Institute of Medical Research (Main Line Health)
Matthew Brain Sarah MineallLaunceston General Hospital
Dai KimuraLe Bonheur Children's Hospital
Luca Brazzi Gabriele Sales Giorgia MontrucchioLe Molinette Hospital (Ospedale Molinette Torino)
Tawnya OgstonLegacy Emanuel Medical Center
Dave Nagpal Karlee FischerLondon Health Sciences Centre
Roberto LorussoMaastricht University Medical Centre
Rajavardhan Rangappa Sujin Rai Argin AppuManipal Hospital Whitefield
Mariano Esperatti Nora Angélica Fuentes Maria Eugenia GonzalezHospital Privado de Comunidad. Mar del Plata. Escuela Superior de Medicina. Universidad Nacional de Mar del Plata
Diarmuid O'BriainMaroondah Hospital
Edmund G. CartonMater Misericordiae University Hospital
Ayan Sen Amanda Palacios Deborah RaineyMayo Clinic College of Medicine
Gordan Samoukoviv Josie CampisiMcGill University Health Centre
Lucia Durham Emily Neumann Cassandra Seefeldt Octavio Falcucci Amanda Emmrich Jennifer Guy Carling Johns Kelly Potzner Catherine Zimmermann Angelia EspinalMedical College of Wisconsin (Froedtert Hospital)
Nina Buchtele Michael Schwameis Andrea Korhnfehl Roman Brock Thomas StaudingerMedical University of Vienna
Stephanie-Susanne Stecher Michaela Barnikel Sófia Antón Alexandra PawlikowskiMedical Department II, LMU Hospital Munich
Akram Zaaqoq Lan Anh Galloway Caitlin MerleyMedStar Washington Hospital Centre
Alistair NicholMonash University
Marc Csete Luisa Quesada Isabela SabaMount Sinai Medical Centre
Daisuke Kasugai Hiroaki Hiraiwa
Taku TanakaNagoya University Hospital
Eva Marwali Yoel Purnama Santi Rahayu Dewayanti Ardiyan Dafsah Arifa Juzar Debby SiagianNational Cardiovascular Center Harapan Kita, Jakarta, Indonesia
Yih-Sharng ChenNational Taiwan University Hospital
Mark OginoNemours Alfred I duPont Hospital for Children
Indrek Ratsep Andra-Maris Post Piret Sillaots Anneli Krund Merili-Helen Lehiste Tanel LepikNorth Estonia Medical Centre
Frank Manetta Effe Mihelis Iam Claire Sarmiento Mangala Narasimhan Michael VarroneNorthwell Health
Mamoru KomatsObihiro-Kosei General Hospital
Julia Garcia-Diaz Catherine HarmonOchsner Clinic Foundation
S. Veena Satyapriya Amar Bhatt Nahush A. Mokadam Alberto Uribe Alicia Gonzalez Haixia Shi Johnny McKeown Joshua Pasek Juan Fiorda Marco EcheverriaOhio State University Medical Centre
Rita MorenoOklahoma Heart Institute
Bishoy ZakharyOregon Health and Science University Hospital (OHSU)
Marco Cavana Alberto CucinoOspedale di Arco (Trento Hospital)
Giuseppe Foti Marco Giani Benedetta FumagalliOspedale San Gerardo
Davide Chiumello Valentina CastagnaOspedale San Paolo
Andrea Dell'Amore Paolo NavalesiPadua University Hospital (Policlinico of Padova)
Hoi-Ping ShumPamela Youde Nethersole Eastern Hospital
Alain VuystekePapworth Hospitals NHS Foundation Trust
Asad Usman Andrew Acker Benjamin Smood Blake Mergler Federico Sertic Madhu Subramanian Alexandra Sperry Nicolas RizerPenn Medicine (Hospital of the University of Pennsylvania)
Erlina Burhan Menaldi Rasmin Ernita Akmal Faya Sitompul Navy Lolong Bhat NaivedhPersahabatan General Hospital
Simon EricksonPerth Children's Hospital
Peter Barrett David Dean
Julia DaughertyPiedmont Atlanta Hospital
Antonio LofortePoliclinico di S. Orsola, Università di Bologna
Irfan Khan Mohammed Abraar Quraishi Olivia DeSantisPresbyterian Hospital Services, Albuquerque
Dominic So Darshana KandambyPrincess Margaret Hospital
Jose M. Mandei Hans NatanaelProf Dr R. D. Kandou General Hospital - Paediatric
Eka YudhaLantang Anastasia LantangProf Dr R. D R. D. Kandou General Hospital - Adult
Surya Oto WijayaDr Sulianti Saroso Hospital
Anna JungProvidence Saint John's Health Centre
George Ng Wing Yiu NgQueen Elizabeth Hospital, Hong Kong
Pauline Yeung Ng Shu FangThe University of Hong Kong
Alexis Tabah Megan Ratcliffe Maree DurouxRedcliffe Hospital
Shingo Adachi Shota NakaoRinku General Medical Center (and Senshu Trauma and Critical Care Center)
Pablo Blanco Ana Prieto Jesús SánchezRio Hortega University Hospital
Meghan NicholsonRochester General Hospital
Warwick Butt Alyssa Serratore Carmel DelzoppoRoyal Children's Hospital
Pierre Janin Elizabeth YaradRoyal North Shore Hospital
Richard Totaro Jennifer ColesRoyal Prince Alfred Hospital
Bambang PujoRSUD Soetomo
Robert Balk Andy Vissing Esha Kapania James Hays Samuel Fox
Garrett Yantosh Pavel MishinRush University, Chicago
Saptadi Yuliarto Kohar Hari Santoso Susanthy DjajalaksanaSaiful Anwar Malang Hospital (Brawijaya University) (Paediatrics)
Arie Zainul FatoniSaiful Anwar Malang Hospital (Brawijaya University) (Adult)
Masahiro FukudaSaiseikai Senri Hospital
Keibun LiuSaiseikai Utsunomiya Hospital
Paolo Pelosi Denise BattagliniSan Martino Hospital
Juan Fernando Masa JiménezSan Pedro de Alcantara Hospital
Diego BastosSao Camilo Cura D'ars
Sérgio GaiãoSão João Hospital Centre, Porto
Desy RusmawatiningtyasSardjito Hospital (Paediatrics)
Young-Jae ChoSeoul National University Bundang Hospital
Su Hwan LeeSeverance Hospital
Tatsuya KawasakiShizuoka Children's Hospital
Laveena MunshiSinai Health Systems (Mount Sinai Hospital)
Pranya Sakiyalak Prompak NitayavardhanaSiriraj Hospital
Tamara SeitzSozialmedizinisches Zentrum Süd – Kaiser-Franz-Josef-Spital
Rakesh Arora David KentSt Boniface Hospital (University of Mannitoba)
Daniel MarinoSt Christopher's Hospital for Children
Swapnil Parwar Andrew Cheng Jennene MillerSt George Hospital
Shigeki Fujitani Naoki ShimizuSt Marianna Medical University Hospital
Jai Madhok Clark OwyangStanford University Hospital
Hergen Buscher Claire ReynoldsSt Vincent's Hospital
Olavi Maasikas AleksanBeljantsev Vladislav MihnovitsTartu University Hospital
Takako Akimoto Mariko Aizawa Kanako Horibe Ryota OnoderaTeine Keijinkai Hospital
Carol Hodgson Aidan Burrell Meredith YoungThe Alfred Hospital
Timothy GeorgeThe Heart Hospital Baylor Plano, Plano
Kiran Shekar Niki McGuinness Lacey IrvineThe Prince Charles Hospital
Brigid FlynnThe University of Kansas Medical Centre
Tomoyuki EndoTohoku Medical and Pharmaceutical University
Kazuhiro SugiyamaTokyo Metropolitan Bokutoh Hospital
Keiki ShimizuTokyo Metropolitan Medical Center
Eddy Fan Kathleen ExcondeToronto General Hospital
Shingo IchibaTokyo Women's Medical University Hospital
Leslie LussierTufts Medical Centre (and Floating Hospital for Children)
Gösta LotzUniversitätsklinikum Frankfurt (University Hospital Frankfurt) (Uniklinik)
Maximilian Malfertheiner Lars Maier Esther DreierUniversitätsklinikum Regensburg (Klinik für Innere Medizin II)
Neurinda Permata KusumastutiUniversity Airlangga Hospital (Paediatric)
Colin McCloskey Al-Awwab Dabaliz Tarek B Elshazly Josiah SmithUniversity Hospital Cleveland Medical Centre (UH Cleveland Hospital)
Konstanty S. Szuldrzynski Piotr BielańskiUniversity Hospital in Krakow
Yusuff HakeemUniversity Hospitals of Leicester NHS Trust (Glenfield Hospital)
Keith WilleUniversity of Alabama at Birmingham Hospital (UAB)
Srinivas MurthyUniversity of British Columbia
Ken Kuljit S. Parhar Kirsten M. Fiest Cassidy Codan Anmol ShahidUniversity of Calgary (Peter Lougheed Centre, Foothills Medical Centre, South Health Campus and Rockyview General Hospital)
Mohamed Fayed Timothy Evans Rebekah Garcia Ashley Gutierrez Hiroaki ShimizuUniversity of California, San Francisco-Fresno Clinical Research Centre
Tae Song Rebecca RoseUniversity of Chicago
Suzanne Bennett Denise RichardsonUniversity of Cincinnati Medical Centre
Giles PeekUniversity of Florida
Lovkesh Arora Kristina Rappapport Kristina Rudolph Zita Sibenaller Lori Stout Alicia WalterUniversity of Iowa
Daniel Herr Nazli VedadiUniversity of Maryland - Baltimore
Robert BartlettUniversity of Michigan Medical Center
Antonio PesentiUniversity of Milan
Shaun Thompson Julie Hoffman Xiaonan YingUniversity of Nebraska Medical Centre
Ryan KennedyUniversity of Oklahoma Health Sciences Centre (OU)
Muhammed ElhadiFaculty of Medicine, University of Tripoli
Matthew Griffee Anna Ciullo Yuri KidaUniversity of Utah Hospital
Ricard Ferrer Roca JordI Riera Sofia Contreras Cynthia AlegreVall d'Hebron University Hospital, Barcelona
Christy Kay Irene Fischer Elizabeth RennerWashington University in St. Louis/ Barnes Jewish Hospital
Hayato TaniguciYokohama City University Medical Center
John Fraser Gianluigi Li Bassi Jacky Suen
Adrian Barnett Nicole White Kristen Gibbons Simon Forsyth Amanda Corley India Pearse Samuel Hinton Gabriella Abbate Halah Hassan Silver Heinsar Varun A Karnik Katrina Ki Hollier F. O'Neill Nchafatso Obonyo Leticia Pretti Pimenta Janice D. Reid Kei Sato Kiran Shekar Aapeli Vuorinen Karin S. Wildi Emily S. Wilson Stephanie YerkovichCOVID-19 Critical Care Consortium
James Lee Daniel Plotkin Barbara Wanjiru Citarella Laura MersonISARIC, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
  46 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

2.  Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study.

Authors:  Amy L Ross Russell; Marc Hardwick; Athavan Jeyanantham; Laura M White; Saumitro Deb; Girvan Burnside; Harriet M Joy; Craig J Smith; Thomas A Pollak; Timothy R Nicholson; Nicholas W S Davies; Hadi Manji; Ava Easton; Stephen Ray; Michael S Zandi; Jonathan P Coles; David K Menon; Aravinthan Varatharaj; Beth McCausland; Mark A Ellul; Naomi Thomas; Gerome Breen; Stephen Keddie; Michael P Lunn; John P S Burn; Graziella Quattrocchi; Luke Dixon; Claire M Rice; George Pengas; Rustam Al-Shahi Salman; Alan Carson; Eileen M Joyce; Martin R Turner; Laura A Benjamin; Tom Solomon; Rachel Kneen; Sarah Pett; Rhys H Thomas; Benedict D Michael; Ian Galea
Journal:  Brain Commun       Date:  2021-07-22

3.  Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium.

Authors:  Sherry H-Y Chou; Ettore Beghi; Raimund Helbok; Elena Moro; Joshua Sampson; Valeria Altamirano; Shraddha Mainali; Claudio Bassetti; Jose I Suarez; Molly McNett
Journal:  JAMA Netw Open       Date:  2021-05-03

4.  Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2.

Authors:  Chiara Robba; Denise Battaglini; Paolo Pelosi; Patricia R M Rocco
Journal:  Expert Rev Respir Med       Date:  2020-06-22       Impact factor: 3.772

5.  Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.

Authors:  Ahmed Yassin; Mohammed Nawaiseh; Ala Shaban; Khalid Alsherbini; Khalid El-Salem; Ola Soudah; Mohammad Abu-Rub
Journal:  BMC Neurol       Date:  2021-03-30       Impact factor: 2.474

6.  Endothelial Dysfunction in the Brain: Setting the Stage for Stroke and Other Cerebrovascular Complications of COVID-19.

Authors:  Maithili Sashindranath; Harshal H Nandurkar
Journal:  Stroke       Date:  2021-04-02       Impact factor: 7.914

7.  Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City.

Authors:  Fernando Daniel Flores-Silva; Miguel García-Grimshaw; Sergio Iván Valdés-Ferrer; Alma Poema Vigueras-Hernández; Rogelio Domínguez-Moreno; Dioselina Panamá Tristán-Samaniego; Anaclara Michel-Chávez; Alejandra González-Duarte; Felipe A Vega-Boada; Isael Reyes-Melo; Amado Jiménez-Ruiz; Oswaldo Alan Chávez-Martínez; Daniel Rebolledo-García; Osvaldo Alexis Marché-Fernández; Samantha Sánchez-Torres; Guillermo García-Ramos; Carlos Cantú-Brito; Erwin Chiquete
Journal:  PLoS One       Date:  2021-04-08       Impact factor: 3.240

8.  Neurological Complications in COVID-19 Patients With ECMO Support: A Systematic Review and Meta-Analysis.

Authors:  Nivedha V Kannapadi; Meghana Jami; Lavienraj Premraj; Eric W Etchill; Katherine Giuliano; Errol L Bush; Bo Soo Kim; Stella Seal; Glenn Whitman; Sung-Min Cho
Journal:  Heart Lung Circ       Date:  2021-10-28       Impact factor: 2.975

9.  Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients.

Authors:  Josef Finsterer; Claudia Stollberger
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.